Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 clinical trials
Also written TQB2102.
Its developmentBy Sino Biopharmaceutical, step by step13 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2024 (5)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 3
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (12) · Fudan University (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Henan Cancer Hospital (1)
Often tested with
Tested in the same studies.
Trastuzumab rezetecan (2) · Camrelizumab (2) · Famitinib (2) · Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 (2) · Benmelstobart (2) · Trifluridine tipiracil drug combination (1) · Anti-HER2 Bispecific Antibody TQB2930 (1) · Dalpiciclib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 3 in phase 3
Studies that test Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102, phase 3 first.
- Jan 2027A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast CancerPhase 3 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Aug 2027A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based DrugsPhase 3 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Sep 2027A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerPhase 3 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- May 2027A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract CancerPhase 1/2 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast CancerRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07043725Written as TQB2102 for injectionHow we know
- Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid TumorsRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07512583Written as TQB2930 injection+TQB2102 for injectionHow we know
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as TQB2102How we know
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingPhase 2Fudan UniversityNCT05749588Written as TQB2102 with TQB2868How we know
- A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract CancerRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06431490Written as TQB2102 for injectionHow we know
- A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based DrugsNot yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07483684Written as TQB2102 InjectionHow we know
- A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene AbnormalityRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06496490Written as TQB2102 for injectionHow we know
- Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.Not yet recruitingPhase 2Henan Cancer HospitalNCT07136974Written as TQB2102How we know
- Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast CancerRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07008976Written as TQB2102 InjectionHow we know
- A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal AdenocarcinomaRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06767800Written as TQB2102 for injection (7.5 mg) +Benmelstobart+ChemotherapyHow we know
- A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic AdvancedRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06798207Written as TQB2102 for injectionHow we know
- A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast CancerRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT07003074Written as TQB2102 for InjectionHow we know
- The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast CancerRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06452706Written as TQB2102 for injectionHow we know
- A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast CancerActive, not recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06561607Written as TQB2102 for InjectionHow we know
- A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast CancerCompletedPhase 1Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06115902Written as TQB2102 for injectionHow we know
- Clinical Trial of the TQB2102 Injection in Patients With Advanced CancersActive, not recruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT05735496Written as TQB2102 injectionHow we know